pomalidomide has been researched along with osteoprotegerin in 1 studies
| Studies (pomalidomide) | Trials (pomalidomide) | Recent Studies (post-2010) (pomalidomide) | Studies (osteoprotegerin) | Trials (osteoprotegerin) | Recent Studies (post-2010) (osteoprotegerin) |
|---|---|---|---|---|---|
| 623 | 121 | 552 | 5,108 | 212 | 2,726 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agnelli, L; Bolzoni, M; Bonomini, S; Giuliani, N; Guasco, D; Neri, A; Rizzoli, V; Storti, P; Todoerti, K; Toscani, D | 1 |
1 other study(ies) available for pomalidomide and osteoprotegerin
| Article | Year |
|---|---|
Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules.
Topics: Antineoplastic Agents; Cell Adhesion Molecules; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Chemokine CCL3; Coculture Techniques; Dose-Response Relationship, Drug; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunologic Factors; Integrin alpha4; Lenalidomide; Multiple Myeloma; Osteoblasts; Osteoprotegerin; RANK Ligand; Reverse Transcriptase Polymerase Chain Reaction; Thalidomide; Tumor Cells, Cultured; Tumor Microenvironment | 2013 |